{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:49:43Z","timestamp":1794368983176,"version":"4.9.0"},"reference-count":100,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocytosis. Cancer Res; 77(6); 1261\u201370. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-16-2234","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T20:55:26Z","timestamp":1488488126000},"page":"1261-1270","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future"],"prefix":"10.1158","volume":"77","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[{"name":"1Department of Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[{"name":"2Division of Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[{"name":"3Department of Dermatology, University of Luebeck, Luebeck, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[{"name":"4Department of Medicine Solna & Mastocytosis Centre, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"6Imagine Institute Universit\u00e9 Paris Descartes, Sorbonne, Paris Cit\u00e9, Centre National de R\u00e9f\u00e9rence des Mastocytoses, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[{"name":"7Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"1Department of Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Escribano","sequence":"additional","affiliation":[{"name":"8Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC\/USAL) Instituto Biosanitario de Salamanca (IBSAL) and Department of Medicine, University of Salamanca, Salamanca, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"9Department of Pathology, University of New Mexico, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"10Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[{"name":"12Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[{"name":"13Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"8Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC\/USAL) Instituto Biosanitario de Salamanca (IBSAL) and Department of Medicine, University of Salamanca, Salamanca, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Virginia Commonwealth University, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[{"name":"16Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bindslev-Jensen","sequence":"additional","affiliation":[{"name":"16Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[{"name":"17Wihuri Research Institute, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Galli","sequence":"additional","affiliation":[{"name":"18Institute of Pathology, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Frank","family":"Austen","sequence":"additional","affiliation":[{"name":"2Division of Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[{"name":"18Institute of Pathology, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[{"name":"19Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"20LBPA CNRS UMR8113, Ecole Normale Sup\u00e9rieure de Cachan, Cachan, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"21Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"2022061706171529700_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"2022061706171529700_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"2022061706171529700_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"2022061706171529700_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"2022061706171529700_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archderm.1963.01590140008002","article-title":"The natural course of urticaria pigmentosa: analysis and follow-up of 112 cases","volume":"87","author":"Caplan","year":"1963","journal-title":"Arch Dermatol"},{"key":"2022061706171529700_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archderm.1954.01540150091008","article-title":"Urticaria pigmentosa appearing as a solitary nodular lesion","volume":"69","author":"Chagrin","year":"1954","journal-title":"Arch Dermatol Syphilol"},{"key":"2022061706171529700_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/archderm.1961.01580170100014","article-title":"Solitary mastocytosis (urticaria pigmentosa)","volume":"84","author":"Johnson","year":"1961","journal-title":"Arch Dermatol"},{"key":"2022061706171529700_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: a review","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"key":"2022061706171529700_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0344-0338(85)80184-9","article-title":"Tissue mast cells in health and disease","volume":"179","author":"Parwaresch","year":"1985","journal-title":"Pathol Res Pract"},{"key":"2022061706171529700_bib10","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"2022061706171529700_bib11","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0889-8588(05)70300-2","article-title":"Serum tryptase and the laboratory diagnosis of systemic mastocytosis","volume":"14","author":"Schwartz","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022061706171529700_bib13","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706171529700_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"2022061706171529700_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/mp.53.4.188","article-title":"Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia","volume":"53","author":"Sotlar","year":"2000","journal-title":"Mol Pathol"},{"key":"2022061706171529700_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"2022061706171529700_bib17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"2022061706171529700_bib18","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"2022061706171529700_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib21","first-page":"291","article-title":"Mastocytosis (mast cell disease)","volume-title":"World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Valent","year":"2001"},{"key":"2022061706171529700_bib22","first-page":"54","article-title":"Mastocytosis (mast cell disease)","volume-title":"World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2008"},{"key":"2022061706171529700_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"2022061706171529700_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"2022061706171529700_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"2022061706171529700_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"2022061706171529700_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"2022061706171529700_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur J Haematol"},{"key":"2022061706171529700_bib30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod Pathol"},{"key":"2022061706171529700_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib32","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2022061706171529700_bib33","article-title":"Mastocytosis","volume-title":"World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2016"},{"key":"2022061706171529700_bib34","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"2022061706171529700_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib36","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"2022061706171529700_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"2022061706171529700_bib38","first-page":"14","article-title":"An unusual tumour of the lung","volume":"107","author":"Ayadi","year":"2015","journal-title":"Pathologica"},{"key":"2022061706171529700_bib39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jcp.39.6.596","article-title":"Mast cell sarcoma of the larynx","volume":"39","author":"Horny","year":"1986","journal-title":"J Clin Pathol"},{"key":"2022061706171529700_bib40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00043426-200102000-00014","article-title":"Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy","volume":"23","author":"Guenther","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022061706171529700_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00277-013-1931-x","article-title":"Mast cell sarcoma mimicking metastatic colon carcinoma","volume":"93","author":"Schwaab","year":"2014","journal-title":"Ann Hematol"},{"key":"2022061706171529700_bib42","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"key":"2022061706171529700_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"2022061706171529700_bib44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"2022061706171529700_bib45","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"2022061706171529700_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2015-07-655100","article-title":"KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression","volume":"127","author":"Garcia-Montero","year":"2016","journal-title":"Blood"},{"key":"2022061706171529700_bib47","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"2022061706171529700_bib48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis","volume":"136","author":"Wiechers","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2022061706171529700_bib50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and invivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib51","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"de Melo Campos","year":"2014","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2013.06.020","article-title":"Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM","volume":"133","author":"Alvarez-Twose","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3324\/haematol.2010.034553","article-title":"Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis","volume":"96","author":"Zanotti","year":"2011","journal-title":"Haematologica"},{"key":"2022061706171529700_bib55","first-page":"97","article-title":"Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases","volume":"28","author":"Manara","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2022061706171529700_bib56","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"2022061706171529700_bib57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022061706171529700_bib58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaci.2013.12.1090","article-title":"Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype","volume":"134","author":"Chan","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706171529700_bib59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"key":"2022061706171529700_bib60","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","author":"Alvarez-Twose","journal-title":"Oncotarget. 2016 Jul 19"},{"key":"2022061706171529700_bib61","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"2022061706171529700_bib62","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2022061706171529700_bib63","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"2022061706171529700_bib64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib65","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"2022061706171529700_bib66","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis","volume":"26","author":"Teodosio","year":"2012","journal-title":"Leukemia"},{"key":"2022061706171529700_bib67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"2022061706171529700_bib68","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"2022061706171529700_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"2022061706171529700_bib70","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"2022061706171529700_bib71","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"2022061706171529700_bib72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"2022061706171529700_bib73","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"2022061706171529700_bib74","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"2022061706171529700_bib75","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"2022061706171529700_bib76","first-page":"93","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","volume":"4","author":"Valent","year":"2014","journal-title":"Am J Blood Res"},{"key":"2022061706171529700_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib78","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"2022061706171529700_bib79","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"2022061706171529700_bib80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib81","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"2022061706171529700_bib82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib83","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"2022061706171529700_bib84","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.exphem.2010.05.006","article-title":"Invitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V","volume":"38","author":"B\u00f6hm","year":"2010","journal-title":"Exp Hematol"},{"key":"2022061706171529700_bib85","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"2022061706171529700_bib86","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib87","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood.V122.21.106.106","article-title":"Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"2022061706171529700_bib88","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706171529700_bib89","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022061706171529700_bib90","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"2022061706171529700_bib91","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"2022061706171529700_bib92","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"2022061706171529700_bib93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"2022061706171529700_bib94","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.4049\/jimmunol.180.8.5466","article-title":"Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens","volume":"180","author":"Mayerhofer","year":"2008","journal-title":"J Immunol"},{"key":"2022061706171529700_bib95","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"2022061706171529700_bib96","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"2022061706171529700_bib97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"2022061706171529700_bib98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1189\/jlb.1112609","article-title":"The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells","volume":"95","author":"Peter","year":"2014","journal-title":"J Leukoc Biol"},{"key":"2022061706171529700_bib99","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V124.21.817.817","article-title":"Identification of a neoplastic stem cell in human mast cell leukemia","volume":"124","author":"Eisenwort","year":"2014","journal-title":"Blood"},{"key":"2022061706171529700_bib100","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Alvarez-Twose","year":"2016","journal-title":"Leukemia"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/6\/1261\/2762685\/1261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/6\/1261\/2762685\/1261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:03:23Z","timestamp":1655474603000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/6\/1261\/624909\/Advances-in-the-Classification-and-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,3,14]]},"published-print":{"date-parts":[[2017,3,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-16-2234","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22416258","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416255.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416261.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416255","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416261","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416252.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416264","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416258.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416252","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22416264.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6509508.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509508","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.727367719.793539110","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}